RXSIGHT INC (RXST) Fundamental Analysis & Valuation

NASDAQ:RXST • US78349D1072

Current stock price

7.07 USD
+0.26 (+3.82%)
At close:
7.07 USD
0 (0%)
After Hours:

This RXST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. RXST Profitability Analysis

1.1 Basic Checks

  • RXST had negative earnings in the past year.
  • In the past year RXST has reported a negative cash flow from operations.
  • RXST had negative earnings in each of the past 5 years.
  • RXST had a negative operating cash flow in each of the past 5 years.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • RXST has a Return On Assets (-12.49%) which is comparable to the rest of the industry.
  • RXST has a Return On Equity of -14.13%. This is in the better half of the industry: RXST outperforms 65.24% of its industry peers.
Industry RankSector Rank
ROA -12.49%
ROE -14.13%
ROIC N/A
ROA(3y)-15.91%
ROA(5y)-23.49%
ROE(3y)-18.07%
ROE(5y)-32.74%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • RXST's Gross Margin of 76.60% is amongst the best of the industry. RXST outperforms 86.63% of its industry peers.
  • RXST's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RXST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.74%
GM growth 5Y45.74%
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. RXST Health Analysis

2.1 Basic Checks

  • RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RXST has been increased compared to 1 year ago.
  • RXST has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RXST has been reduced compared to a year ago.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • RXST has an Altman-Z score of 2.63. This is not the best score and indicates that RXST is in the grey zone with still only limited risk for bankruptcy at the moment.
  • RXST has a better Altman-Z score (2.63) than 65.78% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
  • RXST has a Debt to Equity ratio of 0.00. This is in the better half of the industry: RXST outperforms 74.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.63
ROIC/WACCN/A
WACC9.06%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • RXST has a Current Ratio of 10.95. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
  • RXST's Current ratio of 10.95 is amongst the best of the industry. RXST outperforms 96.79% of its industry peers.
  • A Quick Ratio of 9.75 indicates that RXST has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 9.75, RXST belongs to the top of the industry, outperforming 94.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.95
Quick Ratio 9.75
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. RXST Growth Analysis

3.1 Past

  • RXST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.94%.
  • Looking at the last year, RXST shows a decrease in Revenue. The Revenue has decreased by -3.89% in the last year.
  • RXST shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.73% yearly.
EPS 1Y (TTM)-31.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
Revenue 1Y (TTM)-3.89%
Revenue growth 3Y40%
Revenue growth 5Y55.73%
Sales Q2Q%-18.92%

3.2 Future

  • The Earnings Per Share is expected to decrease by -6.23% on average over the next years.
  • The Revenue is expected to grow by 5.34% on average over the next years.
EPS Next Y-42.16%
EPS Next 2Y-13.62%
EPS Next 3Y-6.23%
EPS Next 5YN/A
Revenue Next Year-1.83%
Revenue Next 2Y3.95%
Revenue Next 3Y5.34%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. RXST Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
  • Also next year RXST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • RXST's earnings are expected to decrease with -6.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.62%
EPS Next 3Y-6.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXST Dividend Analysis

5.1 Amount

  • No dividends for RXST!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXST Fundamentals: All Metrics, Ratios and Statistics

RXSIGHT INC

NASDAQ:RXST (4/30/2026, 8:16:33 PM)

After market: 7.07 0 (0%)

7.07

+0.26 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength15.53
Industry Growth32.3
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners90.03%
Inst Owner Change-0.04%
Ins Owners5.55%
Ins Owner Change0.88%
Market Cap291.78M
Revenue(TTM)134.48M
Net Income(TTM)-38.94M
Analysts52.5
Price Target10.26 (45.12%)
Short Float %14.42%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.49%
Min EPS beat(2)35.1%
Max EPS beat(2)37.88%
EPS beat(4)3
Avg EPS beat(4)16.38%
Min EPS beat(4)-16.68%
Max EPS beat(4)37.88%
EPS beat(8)7
Avg EPS beat(8)18.82%
EPS beat(12)11
Avg EPS beat(12)20.92%
EPS beat(16)15
Avg EPS beat(16)19.42%
Revenue beat(2)2
Avg Revenue beat(2)11.91%
Min Revenue beat(2)6.15%
Max Revenue beat(2)17.67%
Revenue beat(4)2
Avg Revenue beat(4)3.75%
Min Revenue beat(4)-6.3%
Max Revenue beat(4)17.67%
Revenue beat(8)4
Avg Revenue beat(8)2.81%
Revenue beat(12)8
Avg Revenue beat(12)3.36%
Revenue beat(16)12
Avg Revenue beat(16)4.99%
PT rev (1m)-3.14%
PT rev (3m)-3.14%
EPS NQ rev (1m)8.99%
EPS NQ rev (3m)-9.45%
EPS NY rev (1m)-5.94%
EPS NY rev (3m)-32.63%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-4%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-4.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.17
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS3.26
BVpS6.68
TBVpS6.68
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -12.49%
ROE -14.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.6%
FCFM N/A
ROA(3y)-15.91%
ROA(5y)-23.49%
ROE(3y)-18.07%
ROE(5y)-32.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.74%
GM growth 5Y45.74%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.27%
Cap/Sales 2.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.95
Quick Ratio 9.75
Altman-Z 2.63
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)126.95%
Cap/Depr(5y)97.78%
Cap/Sales(3y)4.05%
Cap/Sales(5y)5.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
EPS Next Y-42.16%
EPS Next 2Y-13.62%
EPS Next 3Y-6.23%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.89%
Revenue growth 3Y40%
Revenue growth 5Y55.73%
Sales Q2Q%-18.92%
Revenue Next Year-1.83%
Revenue Next 2Y3.95%
Revenue Next 3Y5.34%
Revenue Next 5YN/A
EBIT growth 1Y-30.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.38%
EBIT Next 3Y-5.36%
EBIT Next 5YN/A
FCF growth 1Y13.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.46%
OCF growth 3YN/A
OCF growth 5YN/A

RXSIGHT INC / RXST Fundamental Analysis FAQ

What is the ChartMill fundamental rating of RXSIGHT INC (RXST) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RXST.


What is the valuation status for RXST stock?

ChartMill assigns a valuation rating of 0 / 10 to RXSIGHT INC (RXST). This can be considered as Overvalued.


How profitable is RXSIGHT INC (RXST) stock?

RXSIGHT INC (RXST) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for RXST stock?

The Earnings per Share (EPS) of RXSIGHT INC (RXST) is expected to decline by -42.16% in the next year.